Concepedia

Bowen's Disease (Squamous Cell Carcinoma In Situ) in Immunosuppressed Patients Treated with Imiquimod 5% Cream and a COX Inhibitor, Sulindac: Potential Applications for This Combination of Immunotherapy

Kathleen J. Smith, Margeruite Germain, Henry G. Skelton

Dermatologic Surgery · 2001 · 66 citations · 23 references

DOI

Abstract

The local immune modulator, 5% imiquimod, in combination with a COX inhibitor, with its many potential antitumor effects may stimulate the innate and possibly the adaptive immune responses to clear these malignancies.

References

23

COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer

Sam Buckman · Carcinogenesis · 1998 · 598 citations

, , +18

Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis

Marina Stolina, Sherven Sharma, Ying Lin et al. · The Journal of Immunology · 2000 · 464 citations · Full text

Molecular pathology of cyclooxygenase-2 in neoplasia.

E Fosslien · PubMed · 2000 · 400 citations

, , +17

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

Karl R. Beutner, John K. Geisse, Donita Helman et al. · Journal of the American Academy of Dermatology · 1999 · 371 citations

, , +11

Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.

Gary A. Piazza, A K Rahm, T S Finn et al. · PubMed · 1997 · 354 citations

, , +17